ERBB2 and breast cancer: In this peculiar metabolic scenario, fatty acid synthase (FASN), an anabolic enzyme required for de novo biosynthesis of palmitic acid, is overexpressed and activated in 85% of HER2 + BC patients and is significantly associated with poor clinical outcome [7].